MYAN SEC-arkivering - MYnd Analytics, Inc.- Årsrapport, fuldmagtserklæring, prospekt

Grundlæggende statistik

LEI	549300U6XU1GKTTNHD15
CIK	822370

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to MYnd Analytics, Inc.

SEC Filings (Chronological Order)

Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.

May 15, 2026	EX-10.1	SALE OF FUTURE RECEIPTS AGREEMENT TERMS AND CONDITIONS 1. Future Receipts: "Future Receipts" includes all payments made by cash, check, Automated Clearing House ("ACH") or other electronic transfer, credit card, debit card, bank card, charge card (ea Initial Periodic Amount $ 56,893.00 What is the Initial Periodic Amount? The Initial Periodic Amount is an estimate of the Specified Percentage of your average sales revenue. We will debit the Periodic Amount from your Bank Account each business week , subject to your actual revenue. We based the Initial Periodic Amount on information you provided or made available to us to calculate your average
May 15, 2026	EX-10.2	PLEASE NOTE: CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Exhibit 10.2 PLEASE NOTE: CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. EXCLUSIVE SUPPLY AGREEMENT This Exclusive Supply Agreement (this "Agreement") is entered into on March 2, 2026 by and between Emmaus Life Sciences, Inc., a Delaware corporation, with its principal executive o
May 15, 2026	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-35527 EMMAUS LIFE SCIENCES, I
May 15, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2026 Emmaus Life Sciences UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2026 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commission
May 15, 2026	EX-99.1	Emmaus Life Sciences Reports Quarterly Financial Results Exhibit 99.1 Emmaus Life Sciences Reports Quarterly Financial Results Torrance CA, May 15, 2026 - Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three months ended March 31, 2026. Highlights “We realized an 18% decline in
April 17, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2026 Emmaus Life Scienc UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2026 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commissi
April 14, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2026 Emmaus Life Scienc UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2026 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commissi
March 31, 2026	EX-10.54	Docusign Envelope ID: FB5B6E03-3012-4E56-8716-8B219B92320A SALE OF FUTURE RECEIPTS AGREEMENT TERMS AND CONDITIONS Guarantor(s)/Seller(s) Initials: 1. Future Receipts: "Future Receipts" includes all payments made by cash, check, Automated Clearing Hou Docusign Envelope ID: FB5B6E03-3012-4E56-8716-8B219B92320A Agreed to by: WILLIS CHANGCHOON LEE Signature: , its CEO (Title) Initials; Exhibit 10.
March 31, 2026	EX-10.10	[SIGNATURES CONTAINED ON THE FOLLOWING PAGE] RREF II PACIFIC CENTER LLC, EMMAUS LIFE SCIENCES, INC., Exhibit 10.10 FIFTH AMENDMENT TO OFFICE LEASE This FIFTH AMENDMENT TO OFFICE LEASE ("Fifth Amendment") is made and entered into effective as of April 15 , 2025 (the "Effective Date") by and between RREF II PACIFIC CENTER LLC, a Delaware limited liability company ("Landlord"), and EMMAUS LIFE SCIENCES, ING., a Delaware corporation ("Tenant"). RECITALS: A. Bixby Torrance, LLC, a Delaware limited lia
March 31, 2026	EX-99.1	Emmaus Life Sciences Reports Annual Financial Results Exhibit 99.1 Emmaus Life Sciences Reports Annual Financial Results Torrance CA, March 30, 2026 - Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the year ended December 31, 2025. Highlights “We experienced a 25% decline in net
March 31, 2026	EX-21.1	List of Registrant’s Subsidiaries Exhibit 21.1 List of Registrant’s Subsidiaries Name Place of incorporation Emmaus Medical, Inc. Delaware Emmaus Medical Japan, Inc. Japan Newfield Nutrition Corp. Delaware Emmaus Medical Europe, Ltd. United Kingdom Emmaus Medical Europe, Ltd. Ireland Emmaus Life Sciences, Co. Ltd Emmaus H&B, Inc. Korea Korea
March 31, 2026	EX-10.52	PURCHASE PRICE: PURCHASED AMOUNT: SPECIFIED PERCENTAGE: INITIAL INSTALLMENT: TOTAL FEES: NET AMOUNT: $ 675,000.00 $ 938,250.00 20% $ 52,125.00 $ 33,800.00 $ 388,075.00 FOR THE SELLER #1 By: Name: LEE WILLIS CHANGCHOON Title: Owner/Agent/Manager FOR T Future Receivables Sale and Purchase Agreement Requirements: Please review and verify your bank account information where indicated, or if it is missing, fill in the correct information on page 17of the agreement.
March 31, 2026	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K e UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES 2EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35527 Emmaus Life Sciences,
March 31, 2026	EX-10.53	Doc ID: b8890a4e0c390e4d0cdb7234a7c918c5c0bb8756 REPRESENTATIONS AND WARRANTIES Each Borrower, jointly and severally, represents and warrants to Collateral Agent and the Lenders as follows: Due Organization, Authorization: Power and Authority. Each B 1 BUSINESS LOAN AND SECURITY AGREEMENT THIS BUSINESS LOAN AND SECURITY AGREEMENT (as the same may be amended, restated, modified, or supplemented from time to time, this “Agreement”) dated as of October 29, 2025(the “Effective Date”) among Agile Capital Funding, LLC as collateral agent (in such capacity, together with its successors and assigns in such capacity, “Collateral Agent”), and Agile Lending, LLC, a Virginia limited liability company (“Lead Lender”) and each assignee that becomes a party to this Agreement pursuant to Section 12.
March 31, 2026	EX-10.55	LICENSE AND EXCLUSIVE DISTRIBUTION AGREEMENT Exhibit 10.55 PLEASE NOTE: CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. LICENSE AND EXCLUSIVE DISTRIBUTION AGREEMENT This License and Exclusive Distribution Agreement (this "Agreement") is entered into as of December 24,2025 (the “Execution Date”), by and between Emmaus Life Sci
March 31, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2026 Emmaus Life Scienc UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2026 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commissi
March 4, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2026 Emmaus Life Science UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2026 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commissio
December 31, 2025	EX-99.1	Emmaus Life Sciences Announces Strategic Transaction Enters into North American License and Exclusive Distribution Agreement Exhibit 99.1 Emmaus Life Sciences Announces Strategic Transaction Enters into North American License and Exclusive Distribution Agreement Torrance CA, December 30, 2025 - Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement wi
December 31, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 24, 2025 Emmaus Life Sci UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 24, 2025 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commi
December 22, 2025	EX-4.1	CONVERTIBLE PROMISSORY Note Exhibit 4.1 NEITHER THIS CONVERTIBLE PROMISSORY NOTE NOR THE SECURITIES ISSUABLE HEREUNDER HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRA
December 22, 2025	EX-10.1	EXCHANGE AGREEMENT Exhibit 10.1 EXCHANGE AGREEMENT This EXCHANGE AGREEMENT (this “Agreement”), dated as of December 17, 2025, is made and entered into by and between Emmaus Life Sciences, Inc., a Delaware corporation, with offices located at 21250 Hawthorne Boulevard, Suite 800, Torrance, CA 90503 (the “Company”), and Dong Seon Kim (the “Investor”), with reference to the following facts: WHEREAS: A. The Investor hol
December 22, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2025 Emmaus Life Sci UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2025 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commi
December 19, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2025 Emmaus Life Sci UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2025 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commi
November 14, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2025 Emmaus Life Sci UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2025 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commi
November 14, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-35527 EMMAUS LIFE SCIENCE
November 14, 2025	EX-10.1	EMMAUS MEDICAL, INC. EMMAUS MEDICAL, INC. EMMAUS MEDICAL, INC. EMMAUS MEDICAL, INC. Exhibit 10.1 Agreement for the Purchase and Sale of Future Receipts Seller's Legal Name: EMMAUS MEDICAL, INC. D/B/A: EMMAUS MEDICAL Form of Business Entity: [ ] Corporation; [ ] Limited Liability Company; [ ] Partnership; [ ] Limited Partnership; [ ] Limited Liability Partnership; [ ] Sole Proprietorship; [ ] Other: Street Address: 21250 HAWTHORNE BLVD STE 800 City: TORRANCE State: CA Zip: 90503 M
November 14, 2025	EX-10.2	Applicable law requires this information to be provided to you to help you make an informed decision. By signing below, you are confirming that you received this Information. Docusign Envelope ID: 694C8383-3FC7-4808-A621-8A3A49AC31EC Exhibit 10.2 Velocity Capital Group Purchased Amount Discount Pursuant to the Revenue Purchase Agreement, the Buyer is entitled to the Specified Percentage of the Seller’s revenue until the purchased amount is paid. However, if the Seller pays the full purchased amount within a period of time from the date of this Agreement, then the Selle
November 14, 2025	EX-99.1	Emmaus Life Sciences Reports Quarterly Financial Results Exhibit 99.1 Emmaus Life Sciences Reports Quarterly Financial Results Torrance CA, November 14, 2025 - Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and nine months ended September 30, 2025. Highlights “We experienc
August 14, 2025	EX-99.1	Emmaus Life Sciences Reports Quarterly Financial Results Exhibit 99.1 Emmaus Life Sciences Reports Quarterly Financial Results Torrance CA, August 14, 2025 - Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and six months ended June 30, 2025. Highlights “We experienced a 48%
August 14, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 Emmaus Life Scien UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commiss
August 14, 2025	EX-10.1	Agreement for the Purchase and Sale of Future Receipts with Agile Capital Exhibit 10.1 Agreement for the Purchase and Sale of Future Receipts Seller's Legal Name: EMMAUS MEDICAL, INC. D/B/A: EMMAUS MEDICAL Form of Business Entity: [ ] Corporation; [ ] Limited Liability Company; [ ] Partnership; [ ] Limited Partnership; [ ] Limited Liability Partnership; [ ] Sole Proprietorship; [ ] Other: Street Address: 21250 HAWTHORNE BLVD STE 800 City: TORRANCE State: CA Zip: 90503 M
August 14, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-35527 EMMAUS LIFE SCIENCES, IN
August 14, 2025	EX-10.2	Future Receivables Sale and Purchase Agreement with iFund Experts Exhibit 10.2 Future Receivables Sale and Purchase Agreement Requirements: • Please review and verify your bank account information where indicated, or if it is missing, fill in the correct information on page 17of the agreement. • MAKE SURE ALL THE REFERENCES ARE FILLED OUT ON THE PAGE 20 • Please return: - CC Processing Statement or A/R Report - Proof of business that has the company EIN for conf
July 1, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2025 Emmaus Life Science UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2025 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commissio
May 15, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 Emmaus Life Sciences UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commission
May 15, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-35527 EMMAUS LIFE SCIENCES, I
May 15, 2025	EX-10.1	Agreement for the Purchase and Sale of Future Receipts with Agile Capital Exhibit 10.1 Agreement for the Purchase and Sale of Future Receipts Seller's Legal Name: EMMAUS MEDICAL, INC. D/B/A: EMMAUS MEDICAL Form of Business Entity: [ ] Corporation; [ ] Limited Liability Company; [ ] Partnership; [ ] Limited Partnership; [ ] Limited Liability Partnership; [ ] Sole Proprietorship; [ ] Other: Street Address: 21250 HAWTHORNE BLVD STE 800 City: TORRANCE State: CA Zip: 90503 M
May 15, 2025	EX-99.1	Emmaus Life Sciences Reports Quarterly Financial Results Exhibit 99.1 Emmaus Life Sciences Reports Quarterly Financial Results Torrance CA, May 15, 2025 - Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three months ended March 31, 2025. Highlights “We are pleased to report that
May 6, 2025	EX-16.1	Letter dated May 5, 2025 from Marcum LLP to the Securities and Exchange Commission Exhibit 16.1 May 5, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Emmaus Life Sciences, Inc. under Item 4.01 of its Form 8- K dated May 5, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Emmaus Life Sciences, Inc. conta
May 6, 2025	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2025 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commission
April 14, 2025	EX-10.48	Agreement for the Purchase and Sale of Future Receipts with Agile Capital dated December 2, 2024 Exhibit 10.48 Agreement for the Purchase and Sale of Future Receipts Seller's Legal Name: EMMAUS MEDICAL, INC. D/B/A: EMMAUS MEDICAL Form of Business Entity: [ ] Corporation; [ ] Limited Liability Company; [ ] Partnership; [ ] Limited Partnership; [ ] Limited Liability Partnership; [ ] Sole Proprietorship; [ ] Other: Street Address: 21250 HAWTHORNE BLVD STE 800 City: TORRANCE State: CA Zip: 90503
April 14, 2025	EX-10.9	Fourth Amendment to Office Lease Agreement dated November 20, 2024 between EMI Holding, Inc. (formerly, Emmaus Life Sciences, Inc.) and RREF Pacific Center LLC. Exhibit 10.9 FOURTH AMENDMENT TO OFFICE LEASE AGREEMENT This FOURTH AMENDMENT TO OFFICE LEASE AGREEMENT (this "Fourth Amendment") is made effective as of November 20, 2024 (the "Effective Date"), by and between RREF II PACIFIC CENTER LLC, a Delaware limited liability company ("Landlord"), and EMMAUS LIFE SCIENCES, INC., a Delaware corporation ("Tenant"). Landlord and Tenant are each sometimes refe
April 14, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K e UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35527 Emmaus Life Sciences, I
April 14, 2025	EX-99.1	Emmaus Life Sciences Reports 2024 Financial Results Exhibit 99.1 Emmaus Life Sciences Reports 2024 Financial Results Torrance CA, April 14, 2025 - Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the year ended December 31, 2024. Recent Highlights “We experienced a decline of nea
April 14, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2025 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commissi
April 14, 2025	EX-21.1	List of Subsidiaries. Exhibit 21.1 List of Registrant’s Subsidiaries Name Place of incorporation Emmaus Medical, Inc. Delaware Emmaus Medical Japan, Inc. Japan Newfield Nutrition Corp. Delaware Emmaus Medical Europe, Ltd. United Kingdom Emmaus Medical Europe, Ltd. Ireland Emmaus Life Sciences, Co. Ltd Korea
April 1, 2025	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-35527 CUSIP Number: 29137T101 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 19, 2024	EX-10.1	Agreement for the Purchase and Sale of Future Receipts with Agile Capital Agreement for the Purchase and Sale of Future Receipts Exhibit 10.1 Seller's Legal Name: EMMAUS MEDICAL, INC. D/B/A: EMMAUS MEDICAL Form of Business Entity: [ ] Corporation; [ ] Limited Liability Company; [ ] Partnership; [ ] Limited Partnership; [ ] Limited Liability Partnership; [ ] Sole Proprietorship; [ ] Other: Street Address: 21250 HAWTHORNE BLVD STE 800 City: TORRANCE State: CA Zip: 90503 M
November 19, 2024	EX-99.1	Emmaus Life Sciences Reports Improved Quarterly Financial Results Exhibit 99.1 Emmaus Life Sciences Reports Improved Quarterly Financial Results Torrance CA, November 19, 2024 - Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and nine months ended September 30, 2024. Highlights “We
November 19, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2024 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commi
November 19, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-35527 EMMAUS LIFE SCIENCE
November 14, 2024	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-35527 CUSIP Number: 29137T101 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 6, 2024	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2024 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commis
October 25, 2024	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2024 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commis
October 4, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 Emmaus Life Sc UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Comm
September 10, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-35527 EMMAUS LIFE SCIENCES, I
September 10, 2024	EX-10.4	Promissory Note dated March 15, 2024 Exhibit 10.4 THIS PROMISSORY NOTE HAS NOT BEEN AND WILL NOT BE REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES AC
September 10, 2024	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2024 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commi
September 10, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-35527 EMMAUS LIFE SCIENCES, IN
September 10, 2024	EX-10.1	Agreement for the Purchase and Sale of Future Receipts with Agile Capital Exhibit 10.1 Agreement for the Purchase and Sale of Future Receipts Seller's Legal Name: EMMAUS MEDICAL, INC. D/B/A:EMMAUS MEDICAL Form of Business Entity: [ ] Corporation; [ ] Limited Liability Company; [ ] Partnership; [ ] Limited Partnership; [ ] Limited Liability Partnership; [ ] Sole Proprietorship; [ ] Other: Street Address: 21250 HAWTHORNE BLVD STE 800 City: TORRANCE State: CA Zip: 90503 Ma
September 10, 2024	EX-16.1	September 10, 2024 Letter of Baker Tilly US, LLP to the Securities and Exchange Commission Exhibit 16.1 Baker Tilly US, LLP 18500 Von Karman Ave; 10th Fl. Irvine, CA 92612 United States of America T: +1 (949) 222 2999 F: +1 (949) 222 2989 bakertilly.com September 10, 2024 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Dear Ladies and Gentlemen: We are the former independent registered public accounting firm for Emmaus Life Sciences, Inc. (the “Company”). We hav
September 10, 2024	EX-99.1	Emmaus Life Sciences Reports Quarterly Financial Results Exhibit 99.1 Emmaus Life Sciences Reports Quarterly Financial Results Torrance CA, September 10, 2024 - Emmaus Life Sciences, Inc. (OTC Markets: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the year quarters ended March 31 and June 30, 2024. Recent Highlights
August 15, 2024	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-35527 CUSIP Number: 29137T101 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
July 17, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2024 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commissio
July 3, 2024	EX-99.1	Emmaus Life Sciences Reports 2023 Financial Results Exhibit 99.1 Emmaus Life Sciences Reports 2023 Financial Results Torrance CA, July 3, 2024 - Emmaus Life Sciences, Inc. (OTCPK: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the year ended December 31, 2023. Recent Highlights “We are pleased to report that we
July 3, 2024	EX-10.20	Amendment No.1 to Convertible Promissory Note of EMI Holding, Inc. (formerly, Emmaus Life Sciences, Inc.) dated as of July 8, 2019 Exhibit 10.20 EMMAUS LIFE SCIENCES, INC. AMENDMENT NO. 1 TO CONVERTIBLE PROMISSORY NOTE This Amendment No. 1 to Convertible Promissory Note (this "Amendment") is made and entered into as of the date of the last signature hereto by and between Emmaus Life Sciences, Inc., a Delaware corporation ("Borrower" or the "Company"), and the undersigned holder (the "Holder") of the Convertible Promissory Not
July 3, 2024	EX-10.41	Promissory Note dated December 1, 2023 issued by registrant to Wei Peu Zen Exhibit 10.41 THIS PROMISSORY NOTE HAS NOT BEEN AND WILL NOT BE REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES A
July 3, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2024 Emmaus Life Sciences UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2024 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commission
July 3, 2024	EX-21.1	List of Subsidiaries. Exhibit 21.1 List of Registrant’s Subsidiaries Name Place of incorporation Emmaus Medical, Inc. Delaware Emmaus Medical Japan, Inc. Japan Newfield Nutrition Corp. Delaware Emmaus Medical Europe, Ltd. United Kingdom Emmaus Medical Europe, Ltd. Ireland Emmaus Life Sciences, Co. Ltd Korea
July 3, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K e UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35527 Emmaus Life Sciences, I
July 3, 2024	EX-10.23	Amendment No. 4 to Convertible Promissory Note of EMI Holding, Inc. (formerly, Emmaus Life Sciences, Inc.) dated as of June 15, 2023. Exhibit 10.23 EMMAUS LIFE SCIENCES, INC. AMENDMENT NO. 4 TO CONVERTIBLE PROMISSORY NOTE This Amendment No. 4 to Convertible Promissory Note (this "Amendment") is made and entered into as of June 15, 2023 by and between EMI Holding, Inc., a Delaware corporation (formerly known as Emmaus Life Sciences, Inc and herein "Borrower" or the "Company"), and the undersigned holder or its registered assigns
May 28, 2024	EX-3.1	Amendment No. 1 to Amended and Restated By-Laws Exhibit 3.1 AMENDMENT NO. 1 TO AMENDED AND RESTATED BY-LAWS OF EMMAUS LIFE SCIENCES, INC. The Amended and Restated By-laws of Emmaus Life Sciences, Inc. (formerly CNS Response, Inc. and MYnd Analytics, Inc.”) are hereby amended to add thereto a new Article VIII as follows: “ARTICLE VIII CERTAIN LITIGATION MATTERS Section 8.01 Delaware Forum. Unless the Corporation consents in writing to the select
May 28, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 Emmaus Life Sciences UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commission
April 1, 2024	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-35527 CUSIP Number: 29137T101 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
February 26, 2024	EX-10.1	Exchange Agreement dated as of February 21, 2024 Exhibit 10.1 EXCHANGE AGREEMENT This EXCHANGE AGREEMENT (this “Agreement”), dated as of February 21, 2024, is made and entered into by and between Emmaus Life Sciences, Inc., a Delaware corporation, with offices located at 21250 Hawthorne Boulevard, Suite 800, Torrance, CA 90503 (the “Company”), and the individuals that are signatories to this Agreement (the “Investors”), with reference to the fol
February 26, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2024 Emmaus Life Sci UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2024 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commi
February 26, 2024	EX-10.2	Form of Joinder Agreement and Amendment to Transfer Restriction and Voting Agreement Exhibit 10.2 THIS JOINDER AREEMENT AND AMENDMENT TO TRANSFER RESTRICTION AND VOTING AGREEMENT (this “Agreement”) is made with reference to the TRANSFER RESTRICTION AND VOTING Agreement (the “Voting Agreement”) made and entered into as of February 8, 2021 by and among between Emmaus Life Sciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the purchaser signature
February 26, 2024	EX-4.1	Form of Convertible Promissory Note Due February 24, 2025 Exhibit 4.1 NEITHER THIS CONVERTIBLE PROMISSORY NOTE NOR THE SECURITIES ISSUABLE HEREUNDER HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRA
December 22, 2023	SC 13G	EMMA / Emmaus Life Sciences, Inc. / Lim Seah H. - SCHEDULE 13G Passive Investment SC 13G 1 ea190621-13gseahemmaus.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION STATEMENT PURSUANT TO RULES 13d-1 AND 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* EMMAUS LIFE SCIENCES, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 29137T101 (CUSIP Nu
December 20, 2023	EX-10.1	Exchange Agreement dated as of December 15, 2023 Exhibit 10.1 EXCHANGE AGREEMENT EXCHANGE AGREEMENT (this “Agreement”), dated as of December 15, 2023, by and between Emmaus Life Sciences, Inc., a Delaware corporation, with offices located at 21250 Hawthorne Boulevard, Suite 800, Torrance, CA 90503 (the “Company”), and the other signatories to this Agreement (the “Investors”), with reference to the following facts. WHEREAS: A. Each of the Investo
December 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2023 Emmaus Life Sci UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2023 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commi
November 14, 2023	EX-10.1	Promissory Note dated July 19, 2023 Exhibit 10.1 OFFER SUMMARY – REVENUE PURCHASE AGREEMENT Funding Provided $581,815.00 This is how much funding AKF INC DBA FundKite will provide. Due to deductions or payments to others, the total funds that will be provided to you directly is $299,930.48. For more information on what amounts will be deducted, please review the attached document “Itemization of Amount Financed." The total funds pro
November 14, 2023	EX-10.3	Promissory Note dated September 28, 2023 DocuSign Envelope ID: C82640C4-3CD9-4A31-B20D-D7F478391F44 Exhibit 10.3 PLEASE READ CAREFULLY Dear Borrower, we are glad to welcome you to our unique financing program. The program will go into effect immediately after you return a signed agreement and will continue to be in effect until we receive the full loan repayment Amount according to this agreement. After we receive the full agreed u
November 14, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-35527 EMMAUS LIFE SCIENCE
November 14, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 Emmaus Life Sci UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commi
November 14, 2023	EX-4.1	Convertible Promissory Note dated September 5, 2023 Exhibit 4.1 NEITHER THIS SECURITY NOR ANY SECURITY INTO WHICH IT IS CONVERTIBLE HAS BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS, AND, ACCORDINGLY, MAY NOT BE PLEDGED, TRANSFERRED, ASSIGNED, OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS OR PURS
November 14, 2023	EX-10.2	Promissory Note dated July 19, 2023 Exhibit 10.2 OFFER SUMMARY – REVENUE BASED FINANCING Funding Provided $582,000.00 This is how much funding CLOUDFUND LLC will provide. Due to deductions or payments to others, the total funds that will be provided to you directly is $275,657.34. For more information on what amounts will be deducted, please review the attached document “Itemization of Amount Financed.” The total funds provided to y
November 14, 2023	EX-99.1	Emmaus Life Sciences Reports Q3 2023 Financial Results Exhibit 99.1 Emmaus Life Sciences Reports Q3 2023 Financial Results Torrance CA, November 14, 2023 - Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and nine months ended September 30, 2023. Recent Highlights “We expe
October 4, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2023 Emmaus Life Scien UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2023 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commiss
August 23, 2023	EX-99.1	Emmaus Life Sciences Reports Management Changes Principal Inventor of Endari® (L-glutamine oral powder) and Long-time Chairman and Chief Executive Officer Free to Purse New Projects Company Appoints Interim Co-Presidents to Focus on Core Business Exhibit 99.1 Emmaus Life Sciences Reports Management Changes Principal Inventor of Endari® (L-glutamine oral powder) and Long-time Chairman and Chief Executive Officer Free to Purse New Projects Company Appoints Interim Co-Presidents to Focus on Core Business Torrance CA, August 23, 2023 - Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the trea
August 23, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2023 Emmaus Life Scien UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2023 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commiss
August 14, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-35527 EMMAUS LIFE SCIENCES, IN
August 14, 2023	EX-10.3	Promissory Note dated May 26, 2023 issued by registrant to Shigeru Matsuda. Exhibit 10.3 EMMAUS MEDICAL JAPAN Promissory Note Principal Amount: JPY90,792,400 Loan Date: 05/26/2023 Currency: Japanese Yen Term: Due on demand Interest Rate: 11.0% Loan Due Date: Due on demand Interest Payment Period: Interest is payable annually Lender: Shigeru Matsuda FOR VALUE RECEIVED, Emmaus Medical, Japan, a Japanese corporation, located at Bizmarks Akasaka 4F, 2-16-6, Ak
August 14, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 Emmaus Life Scien UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commiss
August 14, 2023	EX-10.2	Promissory Note dated May 3, 2023 Exhibit 10.2 APEX FUNDING SOURCE LLC Tel: {646) 518-1521 Sale of Future Receipts Agreement Seller’s Legal Name EMMAUS MEDICAL, INC D/B/A EMMAUS LIFE SCIENCES Form of Business Entity and State of Incorporation Corporation CA Street Address 21250 HAWTHORNE BLVD STE 800 City, State TORRANCE, CA Zip 90503 Mailing Address City, State Zip Primary Contact Name YUTAKA NIIHARA Primary Contact Title Primary
August 14, 2023	EX-10.4	Promissory Note dated June 14, 2023 Exhibit 10.4 15 America Ave Suite 303, Lakewood, NJ 08701 (646) 437-6010 STANDARD MERCHANT CASH ADVANCE AGREEMENT This is an Agreement dated 06/14/2023 by and between Slate Advance (“SA2”) and each merchant listed below (“Merchant”). Merchant’s Legal Name: EMMAUS MEDICAL, INC. and all entities listed on addendum - "MERCHANT LIST" D/B/A: EMMAUS MEDICAL Fed ID #: 87-0419387 Type of Entity: Corporati
August 14, 2023	EX-10.1	Promissory Note dated April 24, 2023 Exhibit 10.1 EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: US$1,830,000 Loan Date: 04/24/2023 Currency: US dollars Term: Due on demand Interest Rate: 11.0% per year Loan Due Date: Due on demand Interest Payment Period: Interest is payable annually Lender: Eastwind ltd. FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800
August 14, 2023	EX-99.1	Emmaus Life Sciences Reports Q2 2023 Financial Results Record Net Revenues Contributed to Income from Operations Sixth Straight Quarterly Increase in Net Revenues Exhibit 99.1 Emmaus Life Sciences Reports Q2 2023 Financial Results Record Net Revenues Contributed to Income from Operations Sixth Straight Quarterly Increase in Net Revenues Torrance CA, August 14, 2023 - Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results
May 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 Emmaus Life Sciences UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commission
May 15, 2023	EX-10.3	Promissory Note dated March 15, 2023 Exhibit 10.3 Congratulations, On Your Preliminary Offer! Dear EMMAUS MEDICAL, INC., This preliminary oﬀer is based on a preliminary review and is not guaranty or commitment that FUNDKITE will consummate a transaction. Complete contracts and documentation described herein must be provided for underwriting review before FUNDKITE will enter into a transaction. Any misrepresentation in the application
May 15, 2023	EX-10.2	Promissory Note dated February 17, 2023 Exhibit 10.2 EMMAUS MEDICAL JAPAN Promissory Note Principal Amount: JPY124,058,736 Loan Date: 02/17/2023 Currency: Japanese Yen Term: 2 Years Interest Rate: 11.0% Loan Due Date: Due on demand Interest Payment Period: Interest is payable annually Lender: Shigeru Matsuda FOR VALUE RECEIVED, Emmaus Medical, Japan, a Japanese corporation, located at Bizmarks Akasaka 4F, 2-16-6, Akasaka, Minato-ku 107-
May 15, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-35527 EMMAUS LIFE SCIENCES, I
May 15, 2023	EX-99.1	Emmaus Life Sciences Reports Q1 2023 Financial Results and Provides Business Update Exhibit 99.1 Emmaus Life Sciences Reports Q1 2023 Financial Results and Provides Business Update Torrance CA, May 15, 2023 - Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three months ended March 31, 2023. Recent Highligh
May 15, 2023	EX-4.4	Common Stock Purchase Warrant dated January 12, 2023 Exhibit 4.4 THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGI
May 15, 2023	EX-10.1	Promissory Note dated February 15, 2023 Exhibit 10.1 THIS PROMISSORY NOTE HAs NOT BEEN AND WILL NOT BE REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES AC
May 15, 2023	EX-10.6	Promissory Note dated March 21, 2023 issued to Yutaka and Soomi Niihara Exhibit 10.6 EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: $127,000.00 Loan Date: March 21, 2023 Interest Rate: 10% per year Loan Due Date: On demand Lender: Yutaka & Soomi Niihara Address for Payment: FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800 Torrance, CA 90503 (“Borrower”), agrees to pay to Lender or his or
May 15, 2023	EX-10.5	Promissory Noted dated March 17, 2023 issued to Hope International Hospice, Inc. Exhibit 10.5 EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: $100,000.00 Loan Date: March 17, 2023 Interest Rate: 10% per year Loan Due Date: On demand Lender: Hope International Hospice, Inc. Address for Payment: FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800 Torrance, CA 90503 (“Borrower”), agrees to pay to Lender
May 15, 2023	EX-10.4	Promissory Note dated March 15, 2023 Exhibit 10.4 OFFER SUMMARY – REVENUE BASED FINANCING Funding Provided $487,058.00 This is how much funding CLOUDFUND LLC will provide. Due to deductions or payments to others, the total funds that will be provided to you directly is $487,058.00. For more information on what amounts will be deducted, please review the attached document “Itemization of Amount Financed.” The total funds provided to y
March 31, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35527 Emmaus Life Sciences, Inc
March 31, 2023	EX-10	Promissory Note dated October 20, 2022 issued to Hope International Hospice, Inc. Exhibit 10.42 EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: $100,000.00 Loan Date: October 20, 2022 Interest Rate: 10% per year Loan Due Date: On demand Lender: Hope International Hospice, Inc. Address for Payment:20705 S. Western Ave., Suite 112 Torrance, CA 90501 FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800 Tor
March 31, 2023	EX-10	Agreement for the Purchase and Sale of Future Receipts with Lendspark Exhibit 10.43 lendspark AGREEMENTFORTHEPURCHASEANDSALE OF FUTURE RECEIPTS ("AGREEMENT") AGREEMENT NO.: 2660 Requirements: - Sign and initial after every "X" on this contract - Fill in the correct account information on the addendum page Exhibit 10.43 Merchant Information: Business Name: EMMAUS LIFE SCIENCES, INC. Email: [email protected] Business Phone: 310-214-0065 Cell Phone: 310-4
March 31, 2023	EX-19	Policy on Insider Trading and Policy Regarding Special Trading Procedures Exhibit 19.1 EMMAUS LIFE SCIENCES, INC. POLICY ON INSIDER TRADING AND POLICY REGARDING SPECIAL TRADING PROCEDURES You should read this Policy address questions to the General Counsel of Emmaus Life Sciences, Inc. (formerly known as MYnd Analytics, Ince) and return the attached acknowledgement to Human Resources. Policy on Insider Trading Emmaus Life Sciences, Inc. including its subsidiaries and af
March 31, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 Emmaus Life Scienc UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commissi
March 31, 2023	EX-99.1	Emmaus Life Sciences Reports 2022 Financial Results and Provides Business Update Exhibit 99.1 Emmaus Life Sciences Reports 2022 Financial Results and Provides Business Update Torrance CA, March 31, 2023 - Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported its results of operation for the year ended December 31, 2022 and an update on recent activities. Yutaka Niihara, M.D., M.
March 7, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2023 Emmaus Life Scie UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2023 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commis
March 7, 2023	EX-4.1	Form of Common Stock Purchase Warrants dated as of January 11, 2023 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAS BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR THE COMPANY SHALL HAVE RECEIVED AN OPINION
March 7, 2023	EX-4.3	Common Stock Purchase Warrant dated January 27, 2023 Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAS BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR THE COMPANY SHALL HAVE RECEIVED AN OPINION
March 7, 2023	EX-4.2	Convertible Promissory Note dated January 18, 2023 Exhibit 4.2 THIS CONVERTIBLE PROMISSORY NOTE AND THE SECURITIES INTO WHICH IT MAY BE CONVERTED HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). NO SALE OR DISPOSITION MAY BE AFFECTED EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT OR AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN APPLICABLE EXEMPTION THEREFROM. THIS NOTE IS REGISTERED WITH THE COMPANY
February 21, 2023	SC 13D/A	EMMA / Emmaus Life Sciences Incorporation / Niihara Yutaka - AMENDMENT NO. 6 TO SCHEDULE 13D Activist Investment SC 13D/A 1 ea173964-13da6niiharaemmaus.htm AMENDMENT NO. 6 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6) Emmaus Life Sciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 29137T101 (CUSIP Number) Yutaka Niihara, M.D., M.P.H. 21250 Hawt
January 19, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2023 Emmaus Life Scie UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2023 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commis
December 12, 2022	8-K	Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2022 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commis
November 15, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 Emmaus Life Sci UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commi
November 15, 2022	EX-99.1	Emmaus Life Sciences Reports Q3 2022 Financial Results and Provides Business Update Exhibit 99.1 Emmaus Life Sciences Reports Q3 2022 Financial Results and Provides Business Update Torrance CA, November 14, 2022 - Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its results of operations and financial condition as of and for the three and nine months ended September30, 2022
November 14, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q y UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-35527 EMMAUS LIFE SCIEN
November 14, 2022	EX-10.2	Promissory Note dated August 15, 2022 Exhibit 10.2 EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: $50,000.00Loan Date: August 15, 2022 Interest Rate: 10% per yearLoan Due Date: On demand Lender: Hope International Hospice, Inc. Address for Payment: FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800 Torrance, CA 90503 (?Borrower?), agrees to pay to Lender or
November 14, 2022	EX-10.5	Promissory Note dated August 17, 2022 Exhibit 10.5 EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: $60,000.00Loan Date: August 17, 2022 Interest Rate: 10% per yearLoan Due Date: On demand Lender: Yutaka & Soomi Niihara Address for Payment: FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800 Torrance, CA 90503 (?Borrower?), agrees to pay to Lender or his or he
November 14, 2022	EX-4.1	Warrant to Purchase Shares of Common Stock dated as of August 9, 2022 Exhibit 4.1 THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGI
November 14, 2022	EX-10.3	Promissory Note dated August 16, 2022 issued to Yutaka and Soomi Niihara Exhibit 10.3 EXHIBIT A TO UNANIMOUS WRITTEN CONSENT EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: $1,668,751.00Loan Date: August 16, 2022 Interest Rate: 10% per yearLoan Due Date: August 16, 2027 Lender: Yutaka and Soomi Niihara Address for Payment: FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800 Torrance, CA 90503
November 14, 2022	EX-10.1	Promissory Note dated July 27, 2022 issued to Yutaka and Soomi Niihara Exhibit 10.1 EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: $402,000.00Loan Date: July 27, 2022 Interest Rate: 12% per yearLoan Due Date: July 31, 2027 Lender: Yutaka and Soomi Niihara Address for Payment: FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800 Torrance, CA 90503 (?Borrower?), agrees to pay to Lender or his
November 14, 2022	EX-10.7	Promissory Note dated September 16, 2022 Exhibit 10.7 THE SECURITIES ISSUABLE UNDER THIS PROMISSORY NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION ST
November 14, 2022	EX-10.6	Promissory Noted dated August 17, 2022 issued to Hope International Hospice, Inc. Exhibit 10.6 EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: $50,000.00Loan Date: August 17, 2022 Interest Rate: 10% per yearLoan Due Date: On demand Lender: Hope International Hospice, Inc. Address for Payment: FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800 Torrance, CA 90503 (?Borrower?), agrees to pay to Lender or
November 14, 2022	EX-10.4	Promissory Note dated August 16, 2022 issued to Yutaka and Soomi Niihara Exhibit 10.4 EXHIBIT A TO UNANIMOUS WRITTEN CONSENT EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: $250,000.00Loan Date: August 16, 2022 Interest Rate: 10% per yearLoan Due Date: August 16, 2027 Lender: Yutaka and Soomi Niihara Address for Payment: FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800 Torrance, CA 90503 (?
November 9, 2022	SC 13D/A	EMMA / Emmaus Life Sciences Inc / Niihara Yutaka - AMENDMENT NO. 5 TO SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5) Emmaus Life Sciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 29137T101 (CUSIP Number) Yutaka Niihara, M.D., M.P.H. 21250 Hawthorne Boulevard, Suite 800 Torrance, California 90503 (310) 214-0065 (Name,
October 31, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D
October 21, 2022	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ D
October 6, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2022 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commiss
September 30, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2022 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Comm
August 19, 2022	EX-10.2	Promissory Note dated August 16, 2022 in the principal amount of $250,000 in favor of Yutaka and Soomi Niihara. Exhibit 10.2 EXHIBIT A TO UNANIMOUS WRITTEN CONSENT EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: $250,000.00 Loan Date: August 16, 2022 Interest Rate: 10% per year Loan Due Date: August 16, 2027 Lender: Yutaka and Soomi Niihara Address for Payment: FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800 Torrance, CA 90503
August 19, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commiss
August 19, 2022	EX-10.3	Promissory Note dated August 15, 2022 in the principal amount of $50,000 in favor of Hope International Hospice, Inc. Exhibit 10.3 EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: $50,000.00 Loan Date: August 15, 2022 Interest Rate: 10% per year Loan Due Date: On demand Lender: Hope International Hospice, Inc. Address for Payment:20705 S. Western Ave., Suite 112 Torrance, CA 90501 FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800 Torran
August 19, 2022	EX-10.1	Promissory Note dated August 16, 2022 in the principal amount of $1,668,751 in favor of Yutaka and Soomi Niihara. Exhibit 10.1 EXHIBIT A TO UNANIMOUS WRITTEN CONSENT EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: $1,668,751.00 Loan Date: August 16, 2022 Interest Rate: 10% per year Loan Due Date: August 16, 2027 Lender: Yutaka and Soomi Niihara Address for Payment: FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800 Torrance, CA 9050
August 15, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commiss
August 15, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-35527 EMMAUS LIFE SCIENCES, IN
August 15, 2022	EX-99.1	Emmaus Life Sciences Reports Q2 2022 Financial Results and Provides Business Update Exhibit 99.1 Emmaus Life Sciences Reports Q2 2022 Financial Results and Provides Business Update Torrance CA, August 15, 2022 - Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported financial results for the three and six months ended June 30, 2022 and provided a business update. Recent Highlights ?
August 10, 2022	EX-99.1	August 4, 2022 Exhibit 99.1 August 4, 2022 VIA E-MAIL Dr. Yutaka Niihara CEO and Chairman of the Board Emmaus Life Sciences, Inc. 21250 Hawthorne Blvd., Suite 800 Torrance, CA 90503 Re: Resignation Dear Yutaka: For the reasons that I have expressed to you in our recent communications, I feel that it is necessary that I resign from the Board and from my associated position on the Audit Committee. I hereby do so.
August 10, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commissi
July 1, 2022	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35527 Emmau
June 30, 2022	D	D X0708 D LIVE 0000822370 Emmaus Life Sciences, Inc. 21250 HAWTHORNE BLVD. SUITE 800 TORRANCE CA CALIFORNIA 90503 310-214-0065 DELAWARE SalesTactix, Inc. MYnd Analytics, Inc. CNS RESPONSE, INC. STRATIVATION, INC. Corporation true Yutaka Niihara 21250 Hawthorne Blvd. Suite 800 Torrance CA CALIFORNIA 90503 Executive Officer Director Chairman and Chief Executive Officer Willis Lee 21250 Hawthorne Blvd.
June 10, 2022	EX-99.1	June 8, 2022 Exhibit 99.1 June 8, 2022 Board of Directors Emmaus Life Sciences, Inc. 21250 Hawthorne Blvd, Suite 800 Torrance, CA 90503 Re: Request for Resignation from the Board Dear Board of Directors: As you are aware, Dr. Yutaka Niihara has requested repeatedly over the last few days that Lori Teranishi, Al Lui and Jane Pine Wood resign from the Board of Directors of Emmaus Life Sciences, Inc., ostensibly
June 10, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commission
May 13, 2022	EX-10.3	Promissory Note dated March 31, 2022 issued to Wei Peu Zen Exhibit 10.3 EMMAUS LIFE SCIENCES, INC. Promissory Note THIS NOTE IS REGISTERED WITH THE COMPANY AS TO BOTH PRINCIPAL AND INTEREST AND, ACCORDINGLY, IS IN ?REGISTERED FORM? WITHIN THE MEANING OF SECTIONS 871(H) AND 881(C) OF THE UNITED STATES INTERNAL REVENUE CODE OF 1986, AS AMENDED. Principal Amount: $200,000.00Loan Date: March 31, 2022 Interest Rate: 10% per yearLoan Due Date: On demand Lender:
May 13, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-35527 EMMAUS LIFE SCIENCES, I
May 13, 2022	EX-99.1	Emmaus Life Sciences Reports Q1 2022 Financial Results and Provides Business Update Exhibit 99.1 Emmaus Life Sciences Reports Q1 2022 Financial Results and Provides Business Update Torrance CA, May 13, 2022 - Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported financial results for the three months ended March 31, 2022 and provided a business update. Recent Highlights ? April 202
May 13, 2022	EX-10.1	Promissory Note dated January 18, 2022 issued to Soomi Niihara Exhibit 10.1 EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: $300,000.00Loan Date: January 18, 2022 Currency:U.S. dollarsTerm: NA Interest Rate:12% per yearLoan Due Date: Due on demand Interest Payment Period: Interest is payable upon Loan Due Date Lender: Soomi Niihara FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800
May 13, 2022	EX-10.2	Form of Promissory Note issued to the persons indicated on Schedule A thereto Exhibit 10.2 EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: $Loan Date: Interest Rate: 10% per yearLoan Due Date: On demand Lender: Address for Payment: FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800 Torrance, CA 90503 (?Borrower?), agrees to pay to Lender or his or her registered assigns (the ?Holder?) the Principa
May 13, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2022 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commission
March 31, 2022	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commissi
March 31, 2022	EX-4.1	Specimen Common Stock Certificate. EXHIBIT 4.1 UMBER EMM [LOGO] SHARES SPECIMEN COMMON STOCK INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE SEE REVERSE FOR CERTAIN DEFINITIONS FULLY PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK OF $0.001 PAR VALUE EACH OF EMMAUS LIFE SCIENCES, INC.transferable on the books of the Corporation in person or by attorney upon surrender of this certificate duly endorsed or assigned. This certifica
March 31, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35527 Emmaus Life Sciences, Inc
March 31, 2022	EX-10.26	Promissory Note dated December 7, 2021 issued by registrant to Soomi Niihara. EXHIBIT 10.26 EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: $700,473.18Loan Date: December 7, 2021 Currency:U.S. dollarsTerm: NA Interest Rate:12% per yearLoan Due Date: Due on demand Interest Payment Period: Interest is payable upon Loan Due Date Lender: Soomi Niihara FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800
March 31, 2022	EX-99.1	Emmaus Life Sciences Reports 2021 Financial Results and Provides Business Update Exhibit 99.1 Emmaus Life Sciences Reports 2021 Financial Results and Provides Business Update Torrance CA, March 31, 2022 - Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported financial results for the year ended December 31, 2021 and an update on recent activities. Recent Highlights ? March 2022:
March 31, 2022	EX-10.22	License Agreement between Kainos Medicine, Inc. and Emmaus Life Sciences, Inc. EXHIBIT 10.22 License Agreement This License Agreement (this "Agreement"), effective as of October 6, 2021 (the "Effective Date"), is made by and between Kainos Medicine, Inc., a corporation organized and existing under the laws of the Republic of Korea, with offices located at 3F, 29, Dunchon-daero 514 beon-gil, Jungwon-gu, Seongnam-si, Gyeonggi-do, Republic of Korea ("Licensor"), and Emmaus Life
March 31, 2022	EX-10.21	Amendment No. 1 to Loan Agreement dated January 5, 2022 between Emmaus Life Sciences, Inc. and EJ Holdings, Inc. EXHIBIT 10.21 AMENDMENT NO. 1 TO LOAN AGREEMENT This Amendment No. 1 to Loan Agreement (this ?Amendment?) is made and entered into on January 5, 2022, by and between Emmaus Life Sciences, Inc. (?Lender?) and EJ Holdings, Inc. (?Borrower?) and amends that certain Loan Agreement dated October 28, 2020 (the ?Original Agreement?) as follows: 1.Defined Terms. Capitalized terms used but not otherwise de
February 17, 2022	SC 13D/A	EMMA / Emmaus Life Sciences Inc / Niihara Yutaka - AMENDMENT NO. 4 TO SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4) Emmaus Life Sciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 29137T101 (CUSIP Number) Yutaka Niihara, M.D., M.P.H. 21250 Hawthorne Boulevard, Suite 800 Torrance, California 90503 (310) 214-0065 (Name,
January 10, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2022 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commiss
December 30, 2021	EX-4.3	Form of Non-Qualified Stock Option Agreement under 2021 Stock Incentive Plan (Non-Employee Director Grantee) Exhibit 4.3 EMMAUS LIFE SCIENCES, INC. 2021 STOCK INCENTIVE PLAN FORM OF NON-QUALIFIED STOCK OPTION AGREEMENT (NON-EMPLOYEE DIRECTOR GRANTEE) 1. Grant of Option. Emmaus Life Sciences, Inc., a Delaware corporation (the ?Company?), grants to (the ?Grantee?), effective , 202 (the ?Grant Date?), an option (the ?Option?) to purchase an aggregate of up to shares (the ?Shares?) of the Company?s common st
December 30, 2021	EX-4.4	Form of Non-Qualified Stock Option Agreement under 2021 Stock Incentive Plan (Non-Director Grantee) Exhibit 4.4 EMMAUS LIFE SCIENCES, INC. 2021 STOCK INCENTIVE PLAN FORM OF NON-QUALIFIED STOCK OPTION AGREEMENT (NON-DIRECTOR GRANTEE) 1. Grant of Option. Emmaus Life Sciences, Inc., a Delaware corporation (the ?Company?), grants to (the ?Grantee?), effective , 202 (the ?Grant Date?), an option (the ?Option?) to purchase an aggregate of up to shares (the ?Shares?) of the Company?s common stock, par
December 30, 2021	EX-4.2	Form of Incentive Stock Option Agreement under 2021 Stock Incentive Plan Exhibit 4.2 EMMAUS LIFE SCIENCES, INC. 2021 STOCK INCENTIVE PLAN FORM OF INCENTIVE STOCK OPTION AGREEMENT 1. Grant of Option. Emmaus Life Sciences, Inc., a Delaware corporation (the ?Company?), grants to (the ?Grantee?), effective , 202 (the ?Grant Date?), an option (the ?Option?) to purchase an aggregate of up to shares (the ?Shares?) of the Company?s common stock, par value $0.001 per share (?Co
December 30, 2021	S-8	As filed with the Securities and Exchange Commission on December 30, 2021 As filed with the Securities and Exchange Commission on December 30, 2021 Registration No.
December 1, 2021	SC 13D/A	EMMA / Emmaus Life Sciences Inc / Niihara Yutaka - AMENDMENT NO. 3 TO SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3) Emmaus Life Sciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 29137T101 (CUSIP Number) Yutaka Niihara, M.D., M.P.H. 21250 Hawthorne Boulevard, Suite 800 Torrance, California 90503 (310) 214-0065 (Name,
November 29, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 23, 2021 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commi
November 12, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-35527 EMMAUS LIFE SCIENCE
October 12, 2021	DEF 14A	2021 Stock Incentive Plan UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? ? ? ? ? Filed by a Party other than the Registrant ? ? ?? Check the appropriate box: ?? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission Only (as permitted by Ru
October 12, 2021	EX-99.1	Emmaus Life Sciences Acquires Key Intellectual Property Rights to Novel IRAK4 Inhibitor From Kainos Medicine Agreement Expands on the Companies’ Collaboration for the Preclinical Development of Potential Anti-Cancer Therapies Exhibit 99.1 Emmaus Life Sciences Acquires Key Intellectual Property Rights to Novel IRAK4 Inhibitor From Kainos Medicine Agreement Expands on the Companies? Collaboration for the Preclinical Development of Potential Anti-Cancer Therapies TORRANCE, Calif., October 12, 2021- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle
October 12, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2021 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commiss
September 30, 2021	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? ? ? ? ? Filed by a Party other than the Registrant ? ? ?? Check the appropriate box: ? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission Only (as permitted by Rul
September 1, 2021	EX-10.2	Promissory Note dated February 17, 2021 issued by registrant to Shigeru Matsuda. Exhibit 10.2 EMMAUS MEDICAL JAPAN Promissory Note Principal Amount: JPY101,687,488Loan Date: 02/17/2021 Currency:Japanese YenTerm: 2 Years Interest Rate:11.0%Loan Due Date: Due on demand Interest Payment Period: Interest is payable annually Lender: Shigeru Matsuda FOR VALUE RECEIVED, Emmaus Medical, Japan, a Japanese corporation, located at 2-20-11 Hongo Bunkyo-ku 113-0033 Tokyo Japan (?Borrower?)
September 1, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-35527 EMMAUS LIFE SCIENCES, IN
September 1, 2021	EX-10.1	Promissory Note dated April 24, 2021 issued by registrant to Eastwind, Ltd. Exhibit 10.1 EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: US$1,500,000Loan Date: 04/24/2021 Currency:US dollarsTerm: Two years Interest Rate:11.0% per yearLoan Due Date: 04/24/2023 Interest Payment Period: Interest is payable annually Lender: Eastwind ltd. FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800, Torrance,
September 1, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-35527 EMMAUS LIFE SCIENCES, I
September 1, 2021	EX-10.2	Promissory Note dated May 26, 2021 issued by registrant to Shigeru Matsuda. Exhibit 10.2 EMMAUS MEDICAL JAPAN Promissory Note Principal Amount: JPY74,420,000Loan Date: 05/26/2021 Currency:Japanese YenTerm: 2 Years Interest Rate:11.0%Loan Due Date: Due on demand Interest Payment Period: Interest is payable annually Lender: Shigeru Matsuda FOR VALUE RECEIVED, Emmaus Medical, Japan, a Japanese corporation, located at 2-20-11 Hongo Bunkyo-ku 113-0033 Tokyo Japan (?Borrower?)
September 1, 2021	EX-10.1	Promissory Note dated January 20, 2021 issued by registrant to Soomi Niihara Exhibit 10.1 EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: $700,000.00Loan Date: January 20, 2021 Currency:U.S. dollarsTerm: NA Interest Rate:12% per yearLoan Due Date: Due on demand Interest Payment Period: Interest is payable upon Loan Due Date Lender: Soomi Niihara FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800
August 26, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q i UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-35527 EMMAUS LIFE SCIENCES,
August 26, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-35527 EMMAUS LIFE SCIENCES, I
August 26, 2021	EX-10.1	Form of Promissory note issued by the registrant to the persons indicated in Schedule A attached to the Form of Promissory Note Exhibit 10.1 EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: Loan Date: Currency:U.S. dollarsTerm: Interest Rate:Loan Due Date: Interest Payment Period: Interest is payable upon Loan Due Date Lender: FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800 Torrance, CA 90503 (?Borrower?) agrees to pay to Lender or her register
August 26, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q i UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-35527 EMMAUS LIFE SCIEN
August 10, 2021	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35527 Emmau
August 10, 2021	8-K	Financial Statements and Exhibits, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commissi
August 10, 2021	EX-99.1	Emmaus Life Sciences Provides SEC Reporting Update 2020 Financial Statements Restated to Reflect Increase in Net Income Attributable to Change in Equity Method Investment in Japanese Affiliate Amended and Restated Form 10-K Includes Complete Restated Exhibit 99.1 Emmaus Life Sciences Provides SEC Reporting Update 2020 Financial Statements Restated to Reflect Increase in Net Income Attributable to Change in Equity Method Investment in Japanese Affiliate Amended and Restated Form 10-K Includes Complete Restated Financial Statements and Currently Dated, Unqualified Audit Report Torrance CA, August 10, 2021 - Emmaus Life Sciences, Inc. (OTC: EMMA)
July 22, 2021	SC 13D/A	US29137T1016 / EMMAUS LIFE SCIENCES INC 0.00000000 / Niihara Yutaka - AMENDMENT NO. 2 TO SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) Emmaus Life Sciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 29137T101 (CUSIP Number) Yutaka Niihara, M.D., M.P.H. 21250 Hawthorne Boulevard, Suite 800 Torrance, California 90503 (310) 214-0065 (Name,
May 19, 2021	EX-99.1	Baker Tilly US, LLP EX-99.1 2 ea141356ex99-1emmauslife.htm LETTER DATED MAY 19, 2020 FROM BAKER TILLY US, LLP Exhibit 99.1 Baker Tilly US, LLP 3655 Nobel Dr; Ste 300 San Diego, CA 92122 United States of America T: +1 (858) 597 4100 F: +1 (858) 597 4111 bakertilly.com May 19, 2021 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Emmaus Life S
May 19, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2021 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commission
May 17, 2021	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-35527 CUSIP Number: 29137T101 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 4, 2021	EX-10.37	Amendment No. 2 to Convertible Promissory Note of EMI Holding, Inc. (formerly, Emmaus Life Sciences, Inc.) dated as of January 15, 2020 Exhibit 10.37 EMI HOLDING, INC. AMENDMENT NO. 2 TO CONVERTIBLE PROMISSORY NOTE This Amendment No. 2 to Convertible Promissory Note (this ?Amendment?) is made and entered into as of January 15, 2020 by and between EMI Holding, Inc., a Delaware corporation (formerly known as Emmaus Life Sciences, Inc and herein ?Borrower? or the ?Company?), and the undersigned holder (the ?Holder?) of the Convertibl
May 4, 2021	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35527 Emmaus Life Sciences, Inc
May 4, 2021	EX-4.25	Form of July 31, 2020 Common Stock Purchase Warrants EXHIBIT 4.25 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
May 4, 2021	EX-10.38	Amendment No. 3 to Convertible Promissory Note as of June 15, 2020 of EMI Holding, Inc. (formerly, Emmaus Life Sciences, Inc.) Exhibit 10.38 EMMAUS LIFE SCIENCES, INC. AMENDMENT NO. 3 TO CONVERTIBLE PROMISSORY NOTE This Amendment No. 3 to Convertible Promissory Note (this ?Amendment?) is made and entered into as of June 15, 2020 by and between EMI Holding, Inc., a Delaware corporation (formerly known as Emmaus Life Sciences, Inc and herein ?Borrower? or the ?Company?), and the undersigned holder or its registered assigns
May 4, 2021	EX-4.27	Form of October 8, 2020 Common Stock Purchase Warrants EX-4.27 4 emma-ex427338.htm EX-4.27 Exhibit 4.27 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EX
May 4, 2021	EX-4.24	Contingent Common Stock Purchase Warrant Exhibit 4.24 THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATIO
March 31, 2021	NT 10-K	- NOTIFICATION OF LATE FILING SEC File Number: 001-35527 CUSIP Number: 29137T101 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
February 22, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2021 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commi
February 22, 2021	EX-10.2	Guaranty dated December 9, 2020 by Emmaus Life Sciences, Inc. in favor or Prestige Capital, Inc. Exhibit 10.2 GUARANTY DATE: December 9, 2020 Prestige Capital Finance, LLC 400 Kelby Street 10th Floor Fort Lee, New Jersey 07024 To induce Prestige Capital Finance, LLC (?Prestige?) to make advances or other financial accommodations to Emmaus Medical, Inc. (?Client?), now or in the future, and with full knowledge that said advances or other financial accommodations would not be made without this
February 22, 2021	EX-10.3	Guaranty dated February 1, 2021 by Emmaus Life Sciences, Inc. in favor of the holders of Amended and Restated 10% Senior Secured Convertible Debentures of EMI Holding, Inc. Exhibit 10.3 GUARANTY Emmaus Life Sciences, Inc., a Delaware corporation (?Guarantor?), as direct or indirect parent corporation of EMI Holding, Inc., a Delaware corporation (the ?Company?), does hereby unconditionally and irrevocably guarantee to each of the holders (each, a ?Holder? and collectively, the ?Holders?) of the Company?s Amended and Restated 10% Senior Secured Convertible Debentures D
February 22, 2021	EX-10.1	Purchase and Sale Agreement dated December 22, 2020 between Emmaus Medical, Inc. and Prestige Capital Finance, LLC. EX-10.1 2 ea135022ex10-1emmauslife.htm PURCHASE AND SALE AGREEMENT DATED , 2021 BETWEEN EMMAUS MEDICAL, INC. AND PRESTIGE CAPITAL FINANCE, LLC Exhibit 10.1 Prestige Capital Finance, LLC 400 KELBY STREET, 10TH FLOOR, FORT LEE, NEW JERSEY 07024 (201) 944-4455 Purchase and Sale Agreement (“Agreement”) 1. ASSIGNMENT. PRESTIGE CAPITAL FINANCE, LLC (“Prestige”) hereby buys and EMMAUS MEDICAL, INC. (“Sel
February 16, 2021	EX-10.2	Transfer Restriction and Voting Agreement dated as of February 8, 2021 between Emmaus Life Sciences, Inc. and the “Purchasers” thereunder. Exhibit 10.2 TRANSFER RESTRICTION AND VOTING AGREEMENT This TRANSFER RESTRICTION AND VOTING Agreement (this ?Agreement?) is made and entered into as of February 8, 2021 by and among between Emmaus Life Sciences, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the purchaser signature pages hereto (each, including its successors and permitted assigns, the ?Purchaser?).
February 16, 2021	EX-10.1	Securities Purchase Agreement dated as of February 8, 2021 among Emmaus Life Sciences, Inc. and the “Purchasers” thereunder, including form of Convertible Promissory Note attached thereto as Exhibit A Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of February 8, 2021, between Emmaus Life Sciences, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the terms and cond
February 16, 2021	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2021 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commis
January 25, 2021	EX-10.28	API Supply Agreement made as of June 16, 2017 between Telcon Inc. (now known as Telcon RF Pharmaceutical Inc.) and Emmaus Life Sciences, Inc. (now known as EMI Holding, Inc.) Exhibit 10.28 API Supply Agreement This Agreement (this “Agreement”), is made and entered into this 16 day of 6, 2017 (the “Effective Date”) by and between Emmaus Life Sciences, Inc., a Delaware corporation with offices at 21250 Hawthorne Blvd., Suite 800, Torrance, California 90503, the United States of America (hereinafter called "Manufacturer") and Telcon Inc., Korea corporation ("Supplier"), w
January 25, 2021	EX-10.27	Raw Material Supply Agreement dated July 12, 2017 between Telcon Inc. (now known as Telcon RF Pharmaceutical Inc.) and Emmaus Life Sciences, Inc. (now known as EMI Holding, Inc.) EX-10.27 9 emma-ex10273369.htm EX-10.27 Confidential Document Exhibit 10.27 Raw Material Supply Agreement Pharmaceutical Grade L-glutamine (PGLG) Emmaus Life Sciences, Inc. Telcon Inc. 1 / 7 Confidential Document Raw Maerial Supply Agreement This Agreement (this “Agreement”), is made by and between Emmaus Life Sciences. Inc. (hereinafter called "Manufacturer") and Telcon Inc. ("Supplier") in order
January 25, 2021	EX-10.33	Letter of Commitment dated December 23, 2019 between EMI Holding, Inc. (formerly, Emmaus Life Sciences, Inc) and Telcon RF Pharmaceutical, Inc. Exhibit 10.33 확 약 서 (Letter of Commitment) Emmaus Life Sciences, Inc. (이하 “엠마우스)는 나스닥(또는 NYSE American)에 상장을 진행 중에 있으며, 상장을 위한 순수자본요건을 충족하기 위하여 엠마우스가 보유한 주식회사 텔콘알에프제약(구 주식회사 텔콘, 이하 “텔콘”) 발행 주식을 처분하기를 희망하는 바, 아래의 사항을 당사자들은 각각 확약하기로 한다. Emmaus Life Sciences, Inc. (“Emmaus”) is in the process of seeking to up-list its common stock on NASDAQ (or NYSE American) and wishes to liquidate the shares of Tel
January 25, 2021	EX-10.37	Credit Access and Loan Agreement dated as of January 10, 2020 by and between Emmaus Life Sciences, Inc. and Yutaka Niihara, M.D., M.P.H. EX-10.37 16 emma-ex10371629.htm EX-10.37 Exhibit 10.37 CREDIT ACCESS AND LOAN AGREEMENT THIS CREDIT ACCESS AND LOAN AGREEMENT (this “Agreement”) is made and entered into on January 10, 2020 by and between Yutaka Niihara, M.D., M.P.H. (“Lender”) and Emmaus Life Sciences, Inc., a Delaware corporation (“Emmaus”), with reference to the following facts: RECITALS: Lender is the Chairman of the Board, Ch
January 25, 2021	EX-3.1	Restated Certificate of Incorporation. EX-3.1 2 emma-ex3112.htm EX-3.1 Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF EMMAUS LIFE SCIENCES, INC. (Originally incorporated on March 20, 1987 under the name of AGE RESEARCH, INC.) ARTICLE I The name of the corporation is Emmaus Life Sciences, Inc. (the “Corporation”). ARTICLE II The registered office of the Corporation in the State of Delaware is 9 E. Loockerman Street, Suite 311, Dov
January 25, 2021	EX-21.1	List of Subsidiaries. Exhibit 21.1 List of Subsidiaries Name Place of incorporation EMI Holding, Inc. Delaware Emmaus Medical, Inc. Delaware Emmaus Medical Japan, Inc. Japan Newfield Nutrition Corporation Delaware Emmaus Medical Europe Limited United Kingdom Emmaus Medical Europe Limited Ireland Emmaus Life Sciences, Co. Ltd. Korea EJ Holdings, Inc. (40% consolidated under the Variable Interest Entity Model) Japan
January 25, 2021	EX-10.26	Amendment for Distributor Agreement entered into as of January 11, 2018 between Telcon Inc. (now known as Telcon RF Pharmaceutical Inc.) and Emmaus Life Sciences, Inc. (now known as EMI Holding, Inc.) EX-10.26 8 emma-ex10261513.htm EX-10.26 Exhibit 10.26 Amendment for Distribution Agreement on June 15, 2017 between Emmaus Life Sciences Inc. and Telcon Inc. Emmaus Life Sciences Inc.와 Telcon Inc.는 2017년 6월15일 체결된 Distribution Agreement 중 하기와 같이 내용을 수정 또는 추가함을 합의 한다. Emmaus Life Sciences Inc. and Telcon Inc. agree to amend or add to the following content in the Distribution Agreement on June 15, 2
January 25, 2021	EX-10.23	Third Amendment to Office Lease Agreement dated September 10, 2019 between EMI Holding, Inc. (formerly, Emmaus Life Sciences, Inc.) and RREF Pacific Center LLC. EX-10.23 6 emma-ex1023941.htm EX-10.23 Exhibit 10.23 EXHIBIT C FORM OF THIRD AMENDMENT TO OFFICE LEASE AGREEMENT THIRD AMENDMENT TO OFFICE LEASE AGREEMENT THIS THIRD AMENDMENT TO OFFICE LEASE AGREEMENT (this "Second Amendment") is made and entered into effective as of September 10, 2019 (the "Effective Date"), by and between RREF II PACIFIC CENTER LLC, a Delaware limited liability company ("Landlo
January 25, 2021	EX-10.12	Promissory Note dated May 26, 2019. Exhibit 10.12 EMMAUS MEDICAL JAPAN Promissory Note Principal Amount: JPY61,000,000Loan Date: 05/26/2019 Currency:Japanese YenTerm: 2 Years Interest Rate:11.0%Loan Due Date: Due on demand Interest Payment Period: Interest is payable annually Lender: Shigeru Matsuda FOR VALUE RECEIVED, Emmaus Medical, Japan, a Japanese corporation, located at 2-20-11 Hongo Bunkyo-ku 113-0033 Tokyo Japan (“Borrower”)
January 25, 2021	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10‑K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001‑35527 Emmaus Life Sciences, Inc
January 25, 2021	EX-10.34	Convertible Bond Purchase Agreement between Emmaus Life Sciences, Inc. and Telcon RF Pharmaceutical, Inc. Exhibit 10.34 주식회사 텔콘알에프제약 제15회 무기명식 이권부 무보증 사모 전환사채 인수계약서 Telcon RF Pharmaceutical, Inc. 15th Bearer-type Interest Purchase Agreement for Unsecured Private Equity Convertible Bonds 발행금액 : 금 삼백억원 (\30,000,000,000) Principal Amount: KRW 30,000,000,000 2020. 09. 28. September 28, 2020 [발행회사] 주식회사 텔콘알에프제약 Issuer: Telcon RF Pharmaceutical, Inc. [인수인] Emmaus Life Sciences, Inc. (엠마우스생명과학) Purchaser: Em
January 25, 2021	EX-10.11	Promissory Note dated April 24, 2019. Exhibit 10.11 EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: US$1,500,000Loan Date: 04/24/2019 Currency:US dollarsTerm: Two years Interest Rate:11.0% per yearLoan Due Date: Due on demand Interest Payment Period: Interest is payable annually Lender: Eastwind ltd. FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800, Torran
January 25, 2021	EX-10.29	Additional Agreement made as of July 2, 2018 between Telcon Inc. (now known as Telcon RF Pharmaceutical Inc.) and Emmaus Life Sciences, Inc. (now known as EMI Holding, Inc.) and add asterixis in Filed/Furnished column. Exhibit 10.29 추 가 합 의 서 ADDITIONAL AGREEMENT 본 추가합의서는 대한민국에 소재한 1) [주식회사 에버코어인베스트먼트홀딩스(구 텔콘홀딩스(주))(이하 “에버코어”)], 2) 주식회사 텔콘알에프제약(구 주식회사 텔콘, 이하 “텔콘”) 및 미합중국에 소재한 3) Emmaus Life Sciences, Inc. (이하 “엠마우 스”)간에 2018. 7. 2. 체결되었다. This ADDITIONAL AGREEMENT (this “Agreement”) is made as of July 2, 2018 by and among (1) Evercore Investment Holdings Co., Ltd. (formerly Telcon Holdings Co. Ltd., “Evercore”),
January 25, 2021	EX-10.30	Agreement dated December 23, 2019 between Telcon RF Pharmaceutical Inc. and Emmaus Life Sciences, Inc. Exhibit 10.30 합 의 서(Agreement) 본 합의서는 대한민국에 소재한 1) 주식회사 텔콘알에프제약(구 주식회사 텔콘, 이하 “텔콘”) 및 미합중국에 소재한 2) Emmaus Life Sciences, Inc. (이하 “엠마우스”)간에 2019. 12. 23. 체결되었다. 텔콘 및 엠마우스(이하 총칭하여 “당사자들”)는 아래와 같이 본 합의서의 내용에 대하여 합의한다. This agreement is executed on December 23, 2019 between 1) Telcon RF Pharmaceutical, Inc. (formerly Telcon Co., Ltd. And herein “Telcon”) in Republic of Korea and 2)Emmaus Life Science
January 25, 2021	EX-10.25	Distributor agreement entered into as of June 15, 2017 between Telcon Inc. (now known as Telcon RF Pharmaceutical Inc.) and Emmaus Life Sciences, Inc. (now known as EMI Holding, Inc.) Exhibit 10.25 Distributor Agreement This Agreement (this “Agreement”), is made and entered into this 15day of 6, 2017 (the “Effective Date”) by and between Emmaus Life Sciences, Inc., a Delaware corporation with offices at 21250 Hawthorne Blvd., Suite 800, Torrance, California 90503, the United States of America (hereinafter called "Manufacturer") and Telcon Inc., Korea corporation ("Distributor")
January 25, 2021	EX-10.35	Right to Sell (Call Option) Agreement between Emmaus Life Sciences, Inc. and Telcon RF Pharmaceutical, Inc. Exhibit 10.35 매도청구권(Call Option-콜옵션) 계약서 Right to Sell (Call Option) Agreement 다음 당사자들은 2020년 9월 28일 다음과 같이 매도청구권(Call Option-콜옵션) 계약(이하 “본 계약”)을 체결한다. This “right to sell(Call Option) agreement” (hereinafter “this agreement”) is executed on September 28, 2020 between the following parties. 1. 발행회사 Issuer 주식회사 텔콘알에프제약 Telcon RF Pharmaceutical, Inc. 대표이사: 김 지 훈 Ji Hoon Kim 주 소: 경기도 용인시 기흥구 공세로 54 (
January 25, 2021	EX-4.1	Specimen Common Stock Certificate. Exhibit 4.1 NUMBER EMM [LOGO] SHARES SPECIMEN COMMON STOCK INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE SEE REVERSE FOR CERTAIN DEFINITIONS FULLY PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK OF $0.001 PAR VALUE EACH OF EMMAUS LIFE SCIENCES, INC.transferable on the books of the Corporation in person or by attorney upon surrender of this certificate duly endorsed or assigned. This certific
November 13, 2020	EX-10.1	Loan Agreement Dated October 28, 2020 Between Emmaus Life Sciences, Inc. and EJ Holdings, Inc EX-10.1 2 ea129796ex10-1emmauslife.htm LOAN AGREEMENT DATED OCTOBER 28, 2020 BETWEEN EMMAUS LIFE SCIENCES, INC. AND EJ HOLDINGS, INC Exhibit 10.1 Loan Agreement Emmaus Life Sciences, Inc. (hereafter “Lender”) and EJ Holdings, Inc. (hereafter “Borrower”) make and enter into this this Loan Agreement (hereafter this “Agreement”) as below. Article 1 (Loan Agreement) The Lender has loaned and agrees to
November 13, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2020 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commis
November 5, 2020	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2020 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commis
November 5, 2020	EX-16.1	Letter dated November 4, 2020 from Squar Milner LLP to the Securities and Exchange Commission Exhibit 16.1 November 4, 2020 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Dear Ladies and Gentleman: We are the former independent registered public accounting firm for Emmaus Life Sciences, Inc. (the “Company”). We have read the Company’s disclosure set forth in Item 4.01 “Changes in Registrant’s Certifying Accountant” of the Company’s Current Report on Form 8-K dated
October 29, 2020	EX-99.1	Hope Delivered : Changing Lives Today The first treatment approved by the FDA for Sickle Cell Disease in nearly 20 years Informational Meeting of Stockholders September 17, 2020 Safe Harbor Statement This presentation by Emmaus Life Sciences, Inc . ( Exhibit 99.1 Hope Delivered : Changing Lives Today The first treatment approved by the FDA for Sickle Cell Disease in nearly 20 years Informational Meeting of Stockholders September 17, 2020 Safe Harbor Statement This presentation by Emmaus Life Sciences, Inc . (“Emmaus” or the “Company”) contains forward - looking statements made pursuant to the safe harbor provisions of the Private Securities Li
October 29, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2020 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commis
October 20, 2020	8-K	Entry into a Material Definitive Agreement - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2020 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Comm
October 8, 2020	8-K/A	Unregistered Sales of Equity Securities, Entry into a Material Definitive Agreement - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2020 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of in
September 25, 2020	8-K/A	Financial Statements and Exhibits - AMENDMENT NO. 1 TO FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2020 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of
September 25, 2020	EX-16.1	Letter dated September 24, 2020 from BDO USA, LLP to the Securities and Exchange Commission Exhibit 16.1 Tel: (310) 557-0300 Fax: (310) 557-1777 www.bdo.com 515 S Flower St, 47th Floor Los Angeles, CA 90071 September 24, 2020 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on September 10, 2020, filed by our former client, Emmaus Life Sciences, Inc. (“Compan
September 24, 2020	EX-10.1	Form of September 22, 2020 Common Stock Purchase Warrants Exhibit 10.1 SECURITIES AMENDMENT AGREEMENT THIS SECURITIES AMENDMENT AGREEMENT (this “Agreement”), dated as of September 22, 2020, is entered into by and among EMI Holding, Inc, a Delaware corporation (the “Company”), Emmaus Life Sciences, Inc., a Delaware corporation and the parent company of EMI (“Emmaus”), and the parties identified as “Holders” on the signature page hereto (the “Holders”). WH
September 24, 2020	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2020 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Comm
September 17, 2020	8-K	Changes in Registrant's Certifying Accountant - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2020 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Comm
September 1, 2020	8-K	- CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2020 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commi
July 31, 2020	EX-99.1	Emmaus Life Sciences Provides Additional Operational and OTC Markets Updates Exhibit 99.1 Emmaus Life Sciences Provides Additional Operational and OTC Markets Updates Torrance CA, July 31, 2020 - Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, provided today additional operational updates for the year ended December 31, 2019 as well as operational updates for the quarters ended March 31 and June 30, 2020 in advance of the filing of its
July 31, 2020	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2020 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commissio
July 8, 2020	8-K	Financial Statements and Exhibits, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2020 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commission
July 8, 2020	EX-99.1	Emmaus Life Sciences to Restate Previously Issued Financial Statements EX-99.1 2 ea123925ex99-1emmauslife.htm PRESS RELEASE DATED JULY 8, 2020 EXHIBIT 99.1 Emmaus Life Sciences to Restate Previously Issued Financial Statements Torrance CA, July 8, 2020 - Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, today announced it will be restating its previously issued audited consolidated financial statements for the twelve months ended De
May 18, 2020	NT 10-Q	- NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC FILE NUMBER 000-15327 FORM 12b-25 CUSIP NUMBER Not applicable NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2020 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Re
May 15, 2020	NT 10-K	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC FILE NUMBER 000-15327 FORM 12b-25 CUSIP NUMBER Not applicable NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form N-SAR ¨ Form N-CSR For Period Ended: December 31, 2019 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition
April 30, 2020	8-K/A	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2020 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commis
April 2, 2020	SC 13D/A	29137T101 / EMMAUS LIFE SCIENCES INC 0.00000000 / Niihara Yutaka - AMENDMENT NO. 1 TO SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Emmaus Life Sciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 29137T101 (CUSIP Number) Yutaka Niihara, M.D., M.P.H. 21250 Hawthorne Boulevard, Suite 800 Torrance, California 90503 (310) 214-0065 (Name,
March 31, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2020 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commissi
March 27, 2020	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2020 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commissi
March 3, 2020	EX-10.1	Registration Rights Agreement dated as of February 28, 2020 between Emmaus Life Sciences, Inc. and Lincoln Park Capital Fund, LLC Exhibit 10.1 Execution Version REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of February 28, 2020, is entered into by and between EMMAUS LIFE SCIENCES, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Investor”). Capitalized terms used he
March 3, 2020	EX-1.1	Purchase Agreement dated as of February 28, 2020 between Emmaus Life Sciences, Inc. and Lincoln Park Capital Fund, LLC Exhibit 1.1 Execution Version PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the “Agreement”), dated as of February 28, 2020 (the “Execution Date”), by and between EMMAUS LIFE SCIENCES, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). Capitalized terms used herein and not otherwise defined herein are defined in S

MYAN / MYnd Analytics, Inc. - SEC-arkivering, Årsberetning, Fuldmagtserklæring

Grundlæggende statistik

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?